In CRC patients, SFRP2, GATA4/5, NDRG4 and VIM were found to be methylated at levels of 57.1% (95% CI, 44.14–69.23%), 42.9% (95% CI, 30.77–55.86%), 83.9% (95%CI, 72.19–91.31%), 28.6% (95% CI, 18.42–41.48%) and 41.1% (95% CI, 29.17–54.12%), respectively. Here, SFRP2 is linked to colorectal carcinoma.